|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Palacio S, McMurry HS, Ali R, Donenberg T,
Silva-Smith R, Wideroff G, Sussman DA, Rocha Lima CMS and Hosein
PJ: DNA damage repair deficiency as a predictive biomarker for
FOLFIRINOX efficacy in metastatic pancreatic cancer. J Gastrointest
Oncol. 10:1133–1139. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rabow MW, Petzel MQB and Adkins SH:
Symptom management and palliative care in pancreatic cancer. Cancer
J. 23:362–373. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stromnes IM and Greenberg PD: Greenberg,
pancreatic cancer: Planning ahead for metastatic spread. Cancer
Cell. 29:774–776. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanda M, Fujii T, Nagai S, Kodera Y,
Kanzaki A, Sahin TT, Hayashi M, Yamada S, Sugimoto H, Nomoto S, et
al: Pattern of lymph node metastasis spread in pancreatic cancer.
Pancreas. 40:951–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGuire S; World Cancer Report 2014, .
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer. WHO press. 2015.Adv Nutr. 7:418–419.
2016. View Article : Google Scholar
|
|
7
|
Giulietti M, Righetti A, Principato G and
Piva F: LncRNA co-expression network analysis reveals novel
biomarkers for pancreatic cancer. Carcinogenesis. 39:1016–1025.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flattet Y, Yasmaguchi T, Andrejevic-Blant
S and Halkic N: Pancreatic adenocarcinoma: The impact of
preneoplastic lesion pattern on survival. Biosci Trends. 9:402–406.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu YJ, Li KZ, Bai JH and Liang ZQ:
C-reactive protein/albumin ratio is a prognostic indicator in
Asians with pancreatic cancers: A meta-analysis. Medicine
(Baltimore). 98:e182192019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schlick K, Magnes T, Huemer F, Ratzinger
L, Weiss L, Pichler M, Melchardt T, Greil R and Egle A: C-reactive
protein and neutrophil/lymphocytes ratio: Prognostic indicator for
doubling overall survival prediction in pancreatic cancer patients.
J Clin Med. 8:E17912019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esteller M: Relevance of DNA methylation
in the management of cancer. Lancet Oncol. 4:351–358. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Espada J and Esteller M: DNA methylation
and the functional organization of the nuclear compartment. Semin
Cell Dev Biol. 21:238–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Misawa K, Mochizuki D, Imai A, Endo S,
Mima M, Misawa Y, Kanazawa T, Carey TE and Mineta H: Prognostic
value of aberrant promoter hypermethylation of tumor-related genes
in early-stage head and neck cancer. Oncotarget. 7:26087–26098.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato N, Fukushima N, Matsubayashi H,
Iacobuzio-Donahue CA, Yeo CJ and Goggins M: Aberrant methylation of
Reprimo correlates with genetic instability and predicts poor
prognosis in pancreatic ductal adenocarcinoma. Cancer. 107:251–257.
2010. View Article : Google Scholar
|
|
15
|
Matsubayashi H, Sato N, Fukushima N, Yeo
CJ, Walter KM, Brune K, Sahin F, Hruban RH and Goggins M:
Methylation of cyclin D2 is observed frequently in pancreatic
cancer but is also an age-related phenomenon in gastrointestinal
tissues. Clin Cancer Res. 9:1446–1452. 2003.PubMed/NCBI
|
|
16
|
Henriksen SD, Madsen PH, Larsen AC,
Johansen MB, Pedersen IS, Krarup H and Thorlacius-Ussing O:
Promoter hypermethylation in plasma-derived cell-free DNA as a
prognostic marker for pancreatic adenocarcinoma staging. Int J
Cancer. 141:2489–2497. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Henriksen SD, Madsen PH, Larsen AC,
Johansen MB, Pedersen IS, Krarup H and Thorlacius-Ussing O:
Cell-free DNA promoter hypermethylation in plasma as a predictive
marker for survival of patients with pancreatic adenocarcinoma.
Oncotarget. 8:93942–93956. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bournet B, Muscari F, Buscail C, Assenat
E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P and
Buscail L: KRAS G12D mutation subtype is a prognostic factor for
advanced pancreatic adenocarcinoma. Clin Transl Gastroenterol.
7:e1572016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee B, Lipton L, Cohen J, Tie J, Javed AA,
Li L, Goldstein D, Burge M, Cooray P, Nagrial A, et al: Circulating
tumor DNA as a potential marker of adjuvant chemotherapy benefit
following surgery for localized pancreatic cancer. Ann Oncol.
30:1472–1478. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loosen SH, Tacke F, Püthe N, Binneboesel
M, Wiltberger G, Alizai PH, Kather JN, Paffenholz P, Ritz T, Koch
A, et al: High baseline soluble urokinase plasminogen activator
receptor (suPAR) serum levels indicate adverse outcome after
resection of pancreatic adenocarcinoma. Carcinogenesis. 40:947–955.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carreras-Torres R, Johansson M, Gaborieau
V, Haycock PC, Wade KH, Relton CL, Martin RM, Davey Smith G and
Brennan P: The role of obesity, type 2 diabetes, and metabolic
factors in pancreatic cancer: A mendelian randomization study. J
Natl Cancer Inst. 109:2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iodice S, Gandini S, Maisonneuve P and
Lowenfels AB: Tobacco and the risk of pancreatic cancer: A review
and meta-analysis. Langenbecks Arch Surg. 393:535–545. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang P, Wang Y, Hang B, Zou X and Mao JH:
A novel gene expression-based prognostic scoring system to predict
survival in gastric cancer. Oncotarget. 7:55343–55351.
2016.PubMed/NCBI
|
|
24
|
R Core Team, . 2012.R: A language and
environment for statistical computing. R Foundation for Statistical
Computing. (Vienna, Austria). ISBN 3-900051-07-0. http://www.R-project.org/
|
|
25
|
Wright RM, et al: Samples and traits for
WGCNA. Cryobiology. 71:5442015.
|
|
26
|
Cao J and Zhang S: A bayesian extension of
the hypergeometric test for functional enrichment analysis.
Biometrics. 70:84–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Balakrishnan R, Harris MA, Huntley R, Van
Auken K and Cherry JM: A guide to best practices for Gene Ontology
(GO) manual annotation. Database (Oxford). 2013:bat0542013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang DW, Sherman BT, Tan Q, Kir J, Liu D,
Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA:
DAVID bioinformatics resources: Expanded annotation database and
novel algorithms to better extract biology from large gene lists.
Nucleic Acids Res. 35:(Web Server Issue). W169–W175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stadler L, et al: Optimizing R language
execution via aggressive speculation. Symposium on Dynamic
Languages. 2016.
|
|
30
|
Zou KH, Tuncali K and Silverman SG:
Correlation and simple linear regression. Radiology. 227:617–622.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nadarajah S and Bakar AAS: A new R package
for actuarial survival models. Computational Statistics.
28:2139–2160. 2013. View Article : Google Scholar
|
|
32
|
Goeman JJ: L1 penalized estimation in the
Cox proportional hazards model. Biom J. 52:70–84. 2010.PubMed/NCBI
|
|
33
|
Horne JS and Garton EO: Likelihood
cross-validation versus least squares cross-validation for choosing
the smoothing parameter in kernel home-range analysis. J Wildlife
Man. 70:641–648. 2011. View Article : Google Scholar
|
|
34
|
Nagy Á, Lánczky A, Menyhárt O and Győrffy
B: Validation of miRNA prognosis power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep. 8:92272018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wakeman CJ, Martin IG, Robertson RW, Dobbs
BR and Frizelle FA: Pancreatic cancer: Management and survival. ANZ
J Surg. 74:941–944. 2015. View Article : Google Scholar
|
|
36
|
Court CM and Hines OJ: The new American
joint committee on cancer TNM staging system for pancreatic
cancer-balancing usefulness with prognostication. JAMA Surg.
153:e1836292018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xia WX, Zhang LH and Liu YW: Weighted gene
co-expression network analysis reveal six hub genes involved in and
tight junction function in pancreatic adenocarcinoma and their
potential use in prognosis. Genet Test Mol Biomarkers. 23:829–836.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gailhouste L, Liew LC, Hatada I, Nakagama
H and Ochiya T: Epigenetic reprogramming using 5-azacytidine
promotes an anti-cancer response in pancreatic adenocarcinoma
cells. Cell Death Dis. 9:4682018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ali S, Cohen C, Little JV, Sequeira JH,
Mosunjac MB and Siddiqui MT: The utility of SMAD4 as a diagnostic
immunohistochemical marker for pancreatic adenocarcinoma, and its
expression in other solid tumors. Diagn Cytopathol. 35:644–648.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sahin IH, Lowery MA, Stadler ZK,
Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP and O'Reilly EM:
Genomic instability in pancreatic adenocarcinoma: A new step
towards precision medicine and novel therapeutic approaches. Expert
Rev Gastroenteral Hepatol. 10:893–905. 2016.
|
|
41
|
Cheng P, Chen Y, He TL, Wang C, Guo SW, Hu
H, Ni CM, Jin G and Zhang YJ: Menin coordinates C/EBPβ-mediated
TGF-β signaling for epithelial-mesenchymal transition and growth
inhibition in pancreatic cancer. Mol Ther Nucleic Acids.
18:155–165. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kumagai T, Akagi T, Desmond JC, Kawamata
N, Gery S, Imai Y, Song JH, Gui D, Said J and Koeffler HP:
Epigenetic regulation and molecular characterization of C/EBPalpha
in pancreatic cancer cells. Int J Cancer. 124:827–833. 2010.
View Article : Google Scholar
|
|
43
|
Yamamoto K, Tateishi K, Kudo Y, Sato T,
Yamamoto S, Miyabayashi K, Matsusaka K, Asaoka Y, Ijichi H, Hirata
Y, et al: Loss of histone demethylase KDM6B enhances aggressiveness
of pancreatic cancer through downregulation of C/EBPα.
Carcinogenesis. 35:2404–2414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamamoto K, Tateishi K, Miyabayashi K,
Yamamoto S, Yotaro Y, Mohri D, Asaoka Y, Ijichi H, Omata M and
Koike K: Reduced Jmjd3 Expression Enhances Aggressiveness of
Pancreatic Cancer Through Downregulation of C/EBPα.
Gastroenterology. 140:S1442011. View Article : Google Scholar
|
|
45
|
Yamada N, Hamada T, Goto M, Tsutsumida H,
Higashi M, Nomoto M and Yonezawa S: MUC2 expression is regulated by
histone H3 modification and DNA methylation in pancreatic cancer.
Int J Cancer. 119:1850–1857. 2010. View Article : Google Scholar
|
|
46
|
Jespersen C, Soragni E, James Chou C,
Arora PS, Dervan PB and Gottesfeld JM: Chromatin structure
determines accessibility of a hairpin polyamide-chlorambucil
conjugate at histone H4 genes in pancreatic cancer cells. Bioorg
Med Chem Lett. 22:4068–4071. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lavorgna A and Harhaj EW: STAMBPL1 is a
deubiquitinating enzyme that regulates HTLV-I Tax subcellular
localization and NF-kB activation. Retrovirology. 8:1. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xiong HQ, Abbruzzese JL, Lin E, Wang L,
Zheng L and Xie K: NF-kappaB activity blockade impairs the
angiogenic potential of human pancreatic cancer cells. Int J
Cancer. 108:181–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Peng T, Zhou W, Guo F, Wu HS, Wang CY,
Wang L and Yang ZY: Centrosomal protein 55 activates NF-κB
signalling and promotes pancreatic cancer cells aggressiveness. Sci
Rep. 7:59252017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Abiatari I, Kiladze M, Kerkadze V, Friess
H and Kleeff J: Expression of YPEL1 in pancreatic cancer cell lines
and tissues. Georgian Medical News. 175:60–62. 2009.
|
|
51
|
Wolpin BM, Michaud DS, Giovannucci EL,
Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma
J, Pollak MN and Fuchs CS: Circulating insulin-like growth factor
binding protein-1 and the risk of pancreatic cancer. Cancer Res.
67:7923–7928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Diaz-Aragon R, Ramirez-Ricardo J,
Cortes-Reynosa P, Simoni-Nieves A, Gomez-Quiroz LE and Perez
Salazar E: Role of phospholipase D in migration and invasion
induced by linoleic acid in breast cancer cells. Mol Cell Biochem.
457:119–132. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Foster DA and Xu L: Phospholipase D in
cell proliferation and cancer. Mol Cancer Res. 1:789–800.
2003.PubMed/NCBI
|
|
54
|
Wang Y, Klumpp S, Amin HM, Liang H, Li J,
Estrov Z, Zweidler-McKay P, Brandt SJ, Agulnick A and Nagarajan L:
SSBP2 is an in vivo tumor suppressor and regulator of LDB1
stability. Oncogene. 29:3044–3053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tilley SK, Kim WY and Fry RC: Analysis of
bladder cancer tumor CpG methylation and gene expression within The
Cancer Genome Atlas identifies GRIA1 as a prognostic biomarker for
basal-like bladder cancer. Am J Cancer Res. 7:1850–1862.
2017.PubMed/NCBI
|
|
56
|
Shu CL, Jing-Yang-Lai, Su LC, Chuu CP and
Fukui Y: SWAP-70: A new type of oncogene. PLoS One. 8:e592452013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jung S, Yi L, Jeong D, Kim J, An S, Oh TJ,
Kim CH, Kim CJ, Yang Y, Kim KI, et al: The role of ADCYAP1,
adenylate cyclase activating polypeptide 1, as a methylation
biomarker for the early detection of cervical cancer. Oncol Rep.
25:245–252. 2011.PubMed/NCBI
|
